Q4 2023 Earnings Call

March 7, 2024

CareRx

Cautionary Statements

Forward Looking Statements

Certain of the statements contained in this presentation are "forward looking information within the meaning of applicable Canadian securities legislation. Forward looking information includes, but is not limited to, business strategy, plans and other expectations, beliefs, goals, objectives, information and statements about possible future events. Forward looking information generally can be identified by the use of forward looking terminology such as “outlook ”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans” or “continue”, or similar expressions suggesting future outcomes or events. You are cautioned not to place undue reliance on such forward-looking information. Forward looking information is based on current expectations, estimates and assumptions that involve a number of risks that are set out under the heading “Risks and Uncertainties” in CareRx’s most recently filed Management’s Discussion and Analysis available on SEDAR+ at www.sedarplus.ca, which could cause actual results to vary and in some instances to differ materially from those anticipated by CareRx and described in the forward looking information contained in this presentation. No assurance can be given that any of the events anticipated by the forward looking information will transpire or occur or, if any of them do so, what benefits CareRx will derive therefrom and neither CareRx nor any other person assumes responsibility for the accuracy and completeness of any forward looking information. Other than as specifically required by applicable laws, CareRx assumes no obligation and expressly disclaims any obligation to update or alter the forward-looking information whether as a result of new information, future events or otherwise.

Non-IFRS Financial Measures and Non-IFRS Ratios

“EBITDA”, “Adjusted EBITDA”, “Adjusted EBITDA Margin” and “Adjusted EBITDA per share” are non-IFRS measures and “Net Debt to Adjusted EBITDA” is a non-IFRS ratio all of which do not have standardized meanings prescribed by IFRS. See “Non-IFRS Financial Measures” , “Non-IFRS Ratios” and “Reconciliation of Non-IFRS Financial Measures” in CareRx’s most recently filed Management’s Discussion and Analysis available on SEDAR+ at www.sedarplus.ca.

All dollar figures are in Canadian dollars unless otherwise stated.

Puneet Khanna

President & Chief Executive Officer

Q4 2023

- Revenue in Q4 2023 of $91.1 million
- Adjusted EBITDA in Q4 2023 of $7.5 million
- Completed comprehensive refinancing of credit facilities

Andrew Mok

Chief Financial Officer

Q4 2023 Financial Results | Revenue



- Average beds serviced of 91,465: -2.5% vs Q4 2022
- Year-over-year revenue decline primarily the result of a change in the mix of branded and generic drugs dispensed during the fourth quarter of 2023. This did not negatively impact profitability in the quarter
- Quarter-over-quarter revenue decreased $2.7 million or 3% primarily due to a small net reduction in the number of beds serviced

Q4 2023 Financial Results | Adjusted EBITDA



- Year-over-year and quarter-over-quarter Adjusted EBITDA increase primarily the result of certain efficiencies and cost savings initiatives implemented during the second half of 2023
- Adjusted EBITDA margin increased to 8.2% or 40 basis points quarter-over-quarter and 60 basis points year-over-year

Q4 2023 Financial Results | Net Income



- Year-over-year decline in net loss driven primarily by decreases in share-based compensation expense and change in fair value of contingent consideration liabilities, in addition to the impact of certain cost savings initiatives implemented during the second half of 2023
- Decline partially offset by a lower gain on change in fair value of derivative financial instruments, intangible assets impairment recorded during the fourth quarter of 2023 and impact of a reduction in the average number of beds serviced
- Quarter-over-quarter net loss driven by reduction in average number of beds serviced, intangible assets impairment and accounting for the refinancing transaction

Comprehensive Debt Refinancing Transaction

- Completed comprehensive $70 million debt refinancing transaction in December 2023 with a syndicate of lenders led by a Canadian Schedule 1 chartered bank
- Legacy term loan, subordinated debt facility and March 2019 convertible debentures repaid in full at close
- Simplified and strengthened capital structure
- Significantly greater financial flexibility
- Expect to initially save up to $1 million annually in interest charges

Balance Sheet

(millions except ratio)

At Dec 31/23	
Cash	$7.0 M
Net Debt[1]	$55.2 M
Net Debt to Adjusted EBITDA[2]	1.8x

- Quarter-over-quarter decrease in cash balance due to completion of comprehensive debt refinancing transaction
- Total debt declined to $62.1 million from $93.4 million[1]
- Improved cash flows from operations to $27.4 million from $22.3 million year-over-year

1. Debt = borrowings (principal) not including November 2019 Convertible Debentures.
2. Annual run-rate based on Q4/23 Adjusted EBITDA.

Puneet Khanna

President & Chief Executive Officer

Operational Optimization

- Procurement initiatives and best practices to augment purchasing power
- Standardized operating model and policies and procedures to enhance operational efficiencies
- Expanding Lean methodology to generate data-driven decisions that increase productivity, promote continuous improvement and drive a performance culture

Prioritizing efficiencies to drive long-term operational performance and sustained profitable growth

Growth Opportunities

Organic Bed Wins

- Increased penetration and broadening scope of services (e.g. Revicare, BOOMR., etc.)
- Leverage scale and capabilities to provide superior pharmacy services offering
- Increased focus on expansion to other congregate care settings
- LTC occupancy increasing post-Covid

New Builds

- Home operators expanding through increased capacity, new construction, new bed license allocations and acquisitions

Home Partner Acquisitions

Tuck-In Acquisitions

- Strong track record of making accretive acquisitions
- Highly fragmented market

Increasingly compelling medium and long-term growth opportunity

2023 Review

- Increased focus on driving efficiencies, improving workflows, standardization of operations
- $16 million equity financing
- Comprehensive debt refinancing transaction
- CEO transition

Questions